Purpose

To compare the effect of 12 months of treatment with moxonidine or bisoprolol on telomerase activity (TA) and parameters characterizing the arterial wall state in postmenopausal women with arterial hypertension (AH) and osteopenia.

Methods

An open-label randomized study with 114 postmenopausal women with hypertension and osteopenia; pulse wave velocity (PWV), intima-media thickness (IMT), and TA were analyzed initially and after 12 months of therapy with moxonidine (n = 57) or bisoprolol (n = 57).

Results

Both medications effectively lowered blood pressure (BP) in both groups. After 12 months, the moxonidine group showed a significant increase in TA by 45.5% (from 0.87 to 1.15; p < 0.001), in contrast to the bisoprolol group, where TA decreased by 14.1% (from 0.89 to 0.74; p = 0.001). Within 12 months, in the moxonidine group, PWV decreased by 1.9% (from 10.35 ± 2.56 to 10.05 ± 2.29 m/s; p = 0.039), and in the bisoprolol group it increased by 5.8% (from 10.36 ± 2.47 to 11.26 ± 2.60 m/s; p < 0.001). In the moxonidine group, IMT increased by 3.5% on the right and 1.4% on the left, in the bisoprolol group – by 5.7% on the right and 4.2% on the left.

Conclusion

A 12-month treatment with moxonidine but not with bisoprolol in postmenopausal women with AH and osteoporosis was associated with a decrease of arterial stiffness seen as statistically significantly reduced PVW and with increased TA.

中文翻译：

---

莫索尼定和比索洛尔对患有动脉高血压和骨质减少的绝经后妇女动脉壁形态功能状况和端粒酶活性的影响。莫斯科随机研究的结果

目的

比较莫索尼定或比索洛尔治疗 12 个月对患有动脉高血压 (AH) 和骨质减少的绝经后妇女端粒酶活性 (TA) 和表征动脉壁状态的参数的影响。

方法

一项针对 114 名患有高血压和骨质减少的绝经后妇女的开放标签随机研究；对脉搏波速度 (PWV)、内膜中层厚度 (IMT) 和 TA 进行了初始和 12 个月莫索尼定 ( n  = 57) 或比索洛尔 (n = 57) 治疗后的分析。

结果

两种药物均有效降低了两组的血压 (BP)。12 个月后，莫索尼定组的 TA 显着增加了 45.5%（从 0.87 到 1.15；p  < 0.001），而比索洛尔组的 TA 减少了 14.1%（从 0.89 到 0.74；p  = 0.001） . 在 12 个月内，在莫索尼定组中，PWV 下降了 1.9%（从 10.35 ± 2.56 到 10.05 ± 2.29 m/s；p  = 0.039），而在比索洛尔组中，它增加了 5.8%（从 10.36 ± 2.47 到 11.26 ± 2.60 米/秒；p  < 0.001）。在莫索尼定组中，IMT 在右侧增加了 3.5%，在左侧增加了 1.4%，在比索洛尔组中，在右侧增加了 5.7%，在左侧增加了 4.2%。

结论

在患有 AH 和骨质疏松症的绝经后妇女中，使用莫索尼定而非比索洛尔进行为期 12 个月的治疗与动脉僵硬度的降低有关，这在统计学上被视为 PVW 显着降低和 TA 增加。